Can-Fite BioPharma Ltd - CANF Enterprise Value-to-Sales Ratio

Official company branding of canfite.com (CANF)

Can-Fite BioPharma (CANF) relies on an asset-light model, delegating molecule synthesis to external contractors. The development strategy is based on licensing agreements with distributors worldwide and the monetization of patents through out-licensing. An enterprise valuation using EV/Sales helps identify the true trend within the sideways corridor, with the current value equal to -5804.88.

Can-Fite (CANF): Company Value to Revenue from 11/23/2025 to 11/20/2026

Can-Fite BioPharma, Ltd. - analytical breakdowns and key metrics (CANF)

Fundamental company valuation:CANF, canfite.com
Manufactured products of Can-Fite BioPharma Ltd

This indicator determines the business value relative to its revenue, excluding the impact of debt load to provide an objective assessment of fundamental value. By analyzing the current EV/Sales level, an investor can see to what extent the market price of Can-Fite BioPharma (CANF) is justified by revenues, while the expected results of final clinical trials for liver disease drugs could serve as a key trigger for a revision of this multiple.